Alison Moore - 23 Mar 2022 Form 4 Insider Report for Allogene Therapeutics, Inc. (ALLO)

Role
Chief Technical Officer
Signature
/s/ Veer Bhavnagri, Attorney-in-Fact for Alison Moore
Issuer symbol
ALLO
Transactions as of
23 Mar 2022
Net transactions value
$0
Form type
4
Filing time
25 Mar 2022, 17:51:18 UTC
Previous filing
17 Mar 2022
Next filing
16 Jun 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALLO Stock Option (Right to Buy) Award $0 +737,179 $0.000000 737,179 23 Mar 2022 Common Stock 737,179 $9.69 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to the stock option shall vest on March 13, 2023, and the remaining shares shall vest in 36 equal monthly installments thereafter.